Dipen Bhuva
New Delhi, DL, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).
Journal: Minerva urology and nephrology
Published: April 23, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).
Journal: Frontiers in immunology
Published: February 05, 2026
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study.
Journal: European urology focus
Published: March 08, 2025
A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.
Journal: BMC cancer
Published: December 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).
Journal: Targeted oncology
Published: August 30, 2024
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Journal: Cancer immunology, immunotherapy : CII
Published: April 01, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
Journal: Cancer immunology, immunotherapy : CII
Published: April 01, 2024
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).
Journal: Cancer immunology, immunotherapy : CII
Published: March 18, 2024
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
Journal: Clinical genitourinary cancer
Published: September 30, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Journal: Minerva urology and nephrology
Published: August 02, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Journal: Targeted oncology
Published: May 22, 2023
Last Updated: 09/26/2026